BMY Fair Value Estimate
$98.9369.9% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Bristol-Myers Squibb Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Did you know?
Capital expenditures increased by 5% from FY24 to FY25.
Current Price
$58.22
-3.91%GoodMoat Value
$98.93
69.9% undervaluedProfile
Valuation (TTM)
Market Cap$118.56B
P/E16.30
EV$150.48B
P/B6.42
Shares Out2.04B
P/Sales2.45
Revenue$48.48B
EV/EBITDA11.56
Bristol-Myers Squibb Company (BMY) Valuation
BMY Valuation Metrics
FCF$12.85B
FCF Growth Rate9.69%
EPS Growth (CAGR)12.72%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →BMY Valuation & Fair Value Analysis
Bristol-Myers Squibb Company (BMY) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Bristol-Myers Squibb Company is $98.93. The current stock price is $58.22, suggesting the stock is 69.9% undervalued.
The price-to-earnings (P/E) ratio is 16.30. Price-to-book ratio is 6.42. Price-to-sales ratio is 2.45. Enterprise value to EBITDA is 11.56. PEG ratio is 1.97.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Bristol-Myers Squibb Company's intrinsic value.